TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: For reducing fatigue, the composition is administered before, during, and/or after the onset of fatigue. The further dissolved oxygen is present in an amount of 20 - 150 parts per million. ACTIVITY - Muscular-Gen.; Immunomodulator. An oxygen-enriched, structured and micro-structured water preparation (test) consisting of hydrogen and oxygen and having negative oxidation-reduction potential was produced and was evaluated for efficacy in maintaining and/or restoring a desired physiological fluid oxygen level in an animal and for fatigue inhibitory activity using a randomized, double blind crossover study. Subjects were tested on four different days during a two-week period. The subjects comprised a group of males and females of at least 18 years in age in good physical condition. None of the test subjects had any history of serious chronic disease. Each of the test subjects had been in physical training during the previous year, training at least 2 times per week, during the time preceding their participation in the present study. The test subjects were randomly assigned to a group to receive the oxygen-enriched, structured and micro-structured water preparation (test) versus a preparation of conventional tap or bottled water (placebo). The total duration of the study was 14 days. Each subject, depending on the group assigned, was asked to drink 500 ml of the oxygen-enriched structured and micro-structured water (test) or 500 ml of the bottled Santa Fe municipal city water (i.e. placebo). Each subject was then asked to sit for 5 minutes. After 5 minutes, a baseline physiological set of measurements were recorded for each subject. These measurements included heart rate, blood oxygen saturation, blood lactate and fatigue assessment. Each subject then underwent a standardized five-step exercise tolerance test to fatigue. During this test, each subject was asked to consume 500 ml of the oxygen-rich, micro-structured water (test) or bottled spring water (placebo), according to the initial test group to which they were originally assigned. The results for test/placebo groups were: mean change in heart rate = 86.93/76; change in oxygen saturation (%) = -2.05/-1.90; mean blood lactate = 11.30/9.43; and mean fatigue assessment = 2.38/1.89 respectively. It was observed that the reduction of change in heart rate during exercise until fatigue indicated that subjects who consumed the oxygen-enriched water increased their endurance by reducing the increase of pulse by 65%. The test group effectively inhibited onset of fatigue as compared to the placebo.    MECHANISM OF ACTION - None given.    ADMINISTRATION - For reducing fatigue, the composition is administered at a dosage of approximately 500 ml orally, topically, parenterally (claimed) (including by subcutaneous injection, intravenously, intramuscularly, intrasternally, by infusion, by inhalation, intra-articularly, intra-synovially, intrathecally, intrahepatically, intralesionally, intracranially, intraperitoneally or transdermally), topically, vaginally, buccally, nasally, by spraying, systemically, intravitreally or rectally.    EXAMPLE - No suitable example given.